SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:oru-100556"
 

Search: onr:"swepub:oai:DiVA.org:oru-100556" > Understanding Study...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Weissler, E. HopeSchool of Medicine, Duke University, Durham, NC, United States (author)

Understanding Study Drug Discontinuation Through EUCLID

  • Article/chapterEnglish2022

Publisher, publication year, extent ...

  • 2022-07-15
  • Frontiers Media S.A.2022
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:oru-100556
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-100556URI
  • https://doi.org/10.3389/fcvm.2022.947645DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Introduction: Disparities in the care and outcomes of peripheral artery disease (PAD) have been well-established. In part this is due to disparities in enrollment of PAD trial cohorts. However, less attention has been paid to non-random protocol non-adherence after enrollment, which may lead to inaccurate estimates of treatment effects and reduce generalizability of study results. We aimed to ascertain characteristics associated with premature study drug discontinuation in a PAD cohort.Methods: Using data from EUCLID (Examining Use of Ticagrelor in Peripheral Artery Disease), factors associated with study drug discontinuation were assessed using univariable and multivariable Cox proportional hazards models with time to study drug discontinuation as the outcome of interest. Relationships between study drug discontinuation and major adverse cardiovascular events (MACE; cardiovascular death, myocardial infarction, ischemic stroke), major adverse limb events (MALE; acute limb ischemia, major amputation, and lower extremity revascularization), and all-cause hospitalization were assessed.Results: Of 13,842 eligible EUCLID participants, 3,886 (28.1%) prematurely and permanently discontinued study drug over a maximum follow-up of 42 months (annualized rate of 13.2 discontinuations per 100 patient-years). In a multivariable model, premature study drug discontinuation was associated with older age (aHR 1.16, 95%CI 1.14-1.19), eligibility based on prior lower extremity revascularization rather than ABI/TBI criteria (aHR 1.14, 95%CI 1.06-1.23), CLI status (aHR 1.23, 95%CI 1.06-1.42), COPD (aHR 1.36, 95%CI 1.24-1.49), and geographic region. In a multivariable analysis, study drug discontinuation was significantly associated with MACE (aHR 3.27, 95%CI 2.90-3.67, p < 0.001), MALE (aHR 1.84, 95%CI 1.63-2.07, p < 0.001), and all-cause hospitalization (aHR 2.37, 95%CI 2.21-2.54) following study drug discontinuation.Conclusions: This analysis of EUCLID demonstrates that premature, permanent discontinuation of study drug is relatively common in more than a quarter of PAD patients, is unevenly distributed based on geography and other baseline characteristics, and is associated with worse outcomes in a clinical trial context. Study teams leading future PAD trials may want to address the possibility of study drug discontinuation prospectively, as a proactive approach may help investigators to maintain study cohort diversity and representativeness without sacrificing power and precision.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Mulder, HillarySchool of Medicine, Duke University, Durham, NC, United States (author)
  • Rockhold, Frank W.School of Medicine, Duke University, Durham, NC, United States (author)
  • Baumgartner, IrisDepartment of Medicine, University of Bern, Bern, Switzerland (author)
  • Norgren, Lars,1942-Örebro universitet,Institutionen för medicinska vetenskaper(Swepub:oru)lsnn (author)
  • Blomster, JuusoFaculty of Medicine, University of Turku, Turku, Finland (author)
  • Katona, Brian G.AstraZeneca, Wilmington, DE, United States (author)
  • Fowkes, F. Gerry R.Centre for Global Health Research, Usher Institute, Edinburgh Medical School, University of Edinburgh, Edinburgh, United Kingdom (author)
  • Mahaffey, KennethSchool of Medicine, Stanford University, Stanford, CA, United States (author)
  • Bonaca, MarcColorado Prevention Center, School of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, United States (author)
  • Patel, Manesh R.School of Medicine, Duke University, Durham, NC, United States (author)
  • Jones, W. SchuylerSchool of Medicine, Duke University, Durham, NC, United States (author)
  • School of Medicine, Duke University, Durham, NC, United StatesDepartment of Medicine, University of Bern, Bern, Switzerland (creator_code:org_t)

Related titles

  • In:Frontiers in Cardiovascular Medicine: Frontiers Media S.A.92297-055X

Internet link

Find in a library

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view